US Market News
2月前
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and UnderstoodApril 18, 2026 10:00 PM
PR Newswire (US)
Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at ScaleDebuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the Perelman School of Medicine, University of Pennsylvania and German Cancer Research Institute (DKFZ)PLEASANTON, Calif., April 18, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale.
Biology is best understood by measuring molecules and cells within intact tissue, where gene expression, cellular states and spatial organization together shape how disease emerges and evolves. Historically, these dimensions have been studied using separate tools, often at limited scale, precluding a complete view of how biological systems function. Spatial biology provides the path toward a comprehensive measurement of biology in its native context.Until now, spatial technologies have been constrained by tradeoffs between scale, sensitivity and gene selection. Atera removes these limitations, enabling the complete measurement of biology, in its native context at single-cell resolution and at scale, without compromise. It marks a fundamental shift in how biology is analyzed and understood.Atera is engineered to enable large-scale whole-transcriptome spatial studies across both fresh-frozen and FFPE tissue, supporting diverse applications in both discovery and translational research."At 10x, our mission is to accelerate the mastery of biology to advance human health," said Serge Saxonov, Chief Executive Officer and Co-founder of 10x Genomics. "Biology is inherently complex, and as much progress as we have made, we still understand only a fraction of how it works. Progress in medicine depends on confronting that complexity directly, which requires measuring biology as it actually functions: systems of individual cells, expressing specific transcripts, in precise locations within tissue. Atera removes the trade-offs that have constrained research, unlocking a new era of insight that will transform our understanding of science and human health."Carl June's Opening Plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2026 will include data from the June Lab's early access samples analyzed on Atera."Spatial tools have always been important in understanding the tumor microenvironment. The samples we work with are rare, collected from glioblastoma patients treated with first-in-human bivalent CAR T cells, so it is critical to capture every layer of information possible," said Andrew Rech, Instructor of Pathology & Laboratory Medicine in the Carl June Lab at the Center for Cellular Immunotherapies at the University of Pennsylvania. "Using Atera has been extremely exciting for advancing our studies because its very high spatial resolution has allowed us to generate tumor microenvironment data from patients treated with CAR T cells, resolve rare immune cells, including T cells, in the post-treatment tumor microenvironment, and better understand tumor dynamics after treatment at a level that was not attainable in our prior lower-plex spatial work."Data presented at AACR by the German Cancer Research Center (DKFZ) will highlight Atera's ability to challenge prevailing assumptions and uncover cancer biology not accessible with legacy approaches. Researchers distinguished multiple malignant and stem cell states, across disease stages, within a single colorectal tumor sample and mapped how these populations interact with the surrounding immune microenvironment. Notably, tumors previously characterized as having limited or low immune infiltration were found to harbor active and diverse immune cell populations, revealing a more complex immune landscape that could inform future therapeutic strategies and drug development.Leading life sciences organizations and research institutions have already committed to utilizing Atera at scale, underscoring strong demand for high-throughput, high-sensitivity spatial analysis across both whole-transcriptome and targeted applications.As the Human Cell Atlas (HCA) continues its mission to map every cell type in the human body, its success will require uncompromised spatial biology at scale, and Atera will enable the consortium to achieve its next set of ambitious goals."Whole-transcriptome spatial transcriptomics transforms tissues into living maps, enabling scientists to visualize complex cellular interactions in disease, uncover hidden mechanisms in clinical specimens and identify new therapeutic targets. Seeing this platform early made it clear that it represents a significant step forward for spatial biology. We expect Atera to fundamentally expand the scope of our translational research and accelerate target discovery in inflammatory and fibrotic diseases," said Kevin Wei, MD, PhD, Brigham and Women's Hospital.Global service providers are moving to adopt Atera to support the next generation of spatial studies. Macrogen, a leading global Contract Research Organization (CRO), along with its U.S. subsidiary Psomagen, has committed to deploying multiple Atera instruments, becoming the first global service provider to adopt the platform. This investment reflects growing demand for high-throughput, uncompromised spatial analysis in biopharma and translational research, and positions Macrogen to support large-scale spatial programs.Atera builds on the momentum and leadership in spatial biology established by Xenium, which remains the trusted solution for generating spatial data today. Bioptimus, a France-based AI biotech company, recently announced its partnership with 10x to build one of the world's largest spatial datasets, STELA, a global initiative to power their multimodal AI platform, M-Optimus. The data will provide the cornerstone of the AI-driven biology and drug discovery engine at Bioptimus. Bioptimus begins with Xenium to generate high-quality spatial data immediately, with plans to expand to Atera in 2027 as increased throughput enables the program to scale toward its full ambition."Atera reflects a first-principles approach to solving a core challenge in biology, which is how to measure complex systems without limitations," said Michael Schnall-Levin, Chief Technology Officer, Chief Strategy Officer and Founding Scientist at 10x Genomics. "We rethought the system from the ground up, optimizing each component across chemistry, hardware and software to enable what was previously impossible in spatial analysis. The result is a platform that delivers whole-transcriptome spatial data with single-cell sensitivity at scale. The Atera platform will substantially expand the scope of questions that can be addressed in spatial biology."To harness the scale of insight generated by Atera's whole-transcriptome studies, 10x is introducing a powerful new cloud analysis platform to securely store, analyze, visualize and collaborate on spatial datasets. Building on the foundation of Xenium Explorer, the new platform brings intuitive visualization into the web and pairs it with GPU-accelerated analysis, empowering biologists to bridge the gap between raw data and insight in minutes instead of hours. Importantly, researchers maintain full control over their data and workflows with Atera routing results to 10x Cloud, customer-managed cloud or on-premise data storage.Broad accessibility to Atera is critical to enabling biological impact. To ensure researchers can access the new platform, regardless of their project size or infrastructure, 10x has launched Catalyst Research Services, enabling direct submission of samples for whole-transcriptome spatial analysis. The program offers flexible access packages, with pre-booking now available and sample processing beginning alongside Atera's commercial availability.10x Genomics at AACR 2026
Atera will be introduced at the AACR Annual Meeting 2026, where 10x will host in-person and digital launch events that include early data generated on the platform; additionally, the company will host an Exhibitor Spotlight Presentation on Atera.Digital Launch Event: Register for the webinar here.Featured Presentations and Posters:Exhibitor Spotlight Presentation: 10x Genomics will introduce Atera, including a presentation from the German Cancer Research Center (DKFZ) with data generated on the platform, on April 19 at 1:30 PM PT in Spotlight Theater C, Sails Pavilion, San Diego Convention Center.Poster #7116: Atera enables clinical-scale spatial studies by overcoming limitations in cost, workflow and performance, generating high-resolution, low-noise datasets optimized for AI-driven biomarker discovery and early cancer detection.Poster #6216: Whole-transcriptome spatial analysis with Atera reveals TME remodeling genes and mitotic signaling at the tumor invasive front, providing new mechanistic insight into tumor progression and immune evasion in cervical and breast cancer.Pre-orders for Atera are now open. The platform is expected to begin shipping in the second half of 2026. 10x Genomics contemplated the launch of Atera when it provided its full-year 2026 financial outlook in February.Additional details on the platform can be found in the Atera media kit.About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2025 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-introduces-atera-a-new-platform-to-redefine-how-biology-is-measured-and-understood-302746542.htmlSOURCE 10x Genomics, Inc.
Original: 10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
US Market News
3月前
Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical LabsMarch 25, 2026 7:00 AM
PR Newswire (US)
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world todayThe Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal atlas, starting in oncology and immunology tissue, designed to generate harmonized multi-omics patient data.A Strategic Partnership with 10x Genomics: Leveraging the Xenium spatial transcriptomics platform as the foundational partner for the launch, the initiative sets a new benchmark for reproducible, AI-ready data generation across leading research institutions worldwide.A Strategic Partnership with the Broad Clinical Labs: A multi-year agreement with Broad Clinical Laboratories to support STELA via the generation of spatial biology data at scale.Profiling Up to 100,000 Patient Specimens: Representing a ~20-fold increase in scale over existing spatial biology atlases, STELA will integrate spatial technologies, pathology imaging, multi-omics, and longitudinal clinical data across three continents.PARIS, March 25, 2026 /PRNewswire/ -- Bioptimus, a global AI company building the world's first world model for biology, today announced the launch of its Spatial Tissue Embedding Learning Atlas (STELA), a multinational spatial data generation initiative anchored by a partnership with 10x Genomics, Inc. (Nasdaq: TXG) and Broad Clinical Labs.
While foundation models for language have thrived on vast digital datasets, biology has long lacked the standardized, high-quality data scale required for a similar breakthrough, particularly for clinical data; Bioptimus is closing this gap by building the data infrastructure necessary to power M-Optimus, the first multimodal and multiscale world model of biology. STELA will serve as the data backbone for M-Optimus, generating massive datasets designed to decrypt the complex organization of human tissues. M-Optimus will leverage this massive multimodal repository to map how molecular and cellular interactions drive disease in fields like oncology and inflammation, ultimately allowing researchers to anticipate patient responses to novel therapies, accelerate drug development, and design more effective immunotherapies.Starting with 10x Genomics'' Xenium spatial transcriptomics and designed to integrate additional spatial and molecular profiling technologies over time, STELA will generate harmonized datasets, integrating: high-resolution spatial transcriptomics, matched histopathology imaging, multi-omics data (e.g., genomics, transcriptomics and proteomics), with longitudinal clinical records. The initiative aims to profile up to 100,000 patient tissue specimens across three continents: the United States, Europe, and Asia, establishing the world's largest clinically linked, spatially profiled, multimodal patient data atlas.Participating hospitals and research institutions will contribute samples under standardized protocols and, in return, receive access to rich spatial characterization and foundation model capabilities. This collaboration empowers clinicians to turn raw data into actionable insights through more precise diagnostic and therapeutic strategies. By aligning data generation protocols, data processing and storage, and AI model development within a unified framework at a diverse, global scale, STELA establishes foundational infrastructure for the next era of biological AI."Today, most patients' diagnostic data is used to inform decisions for only that individual. We envision a world where every patient can contribute insights to better inform the care and treatment outcomes of future patients; just as patients with other diseases, other heritage and even from the past are informing their treatment," said Jean Philippe Vert, PhD, Co-Founder and CEO of Bioptimus. "STELA is the fuel to power M-Optimus, allowing us to map the intricate interactions between cells and tissues, across indications, at unprecedented scales, unlocking a new era of precision medicine."Industry-Shaping PartnershipsThe collaboration between Bioptimus and 10x Genomics aligns advanced spatial biology technologies with large-scale AI foundation model development, bringing together complementary capabilities to reshape how biomedical data is generated and applied. Using the Xenium platform, STELA will generate highly standardized spatial datasets across participating institutions worldwide, enabling the large-scale, reproducible data generation required for large-scale AI model development."Many of the most important questions in medicine come down to understanding how cells interact within complex human tissues," said Serge Saxonov, Chief Executive Officer and Co-founder of 10x Genomics. "By enabling spatial profiling at unprecedented scale, STELA will generate foundational datasets that allow researchers to connect the underlying biology with disease outcomes, unlocking new insights that can accelerate and improve therapeutic discovery and development."Bioptimus will anchor its STELA initiative through a landmark collaboration with the Broad Clinical Laboratories, bridging industrial-scale data generation with frontier AI research. This partnership leverages Broad's high-throughput spatial biology capabilities to process biological samples at scale, creating a massive-scale repository of high-resolution spatial transcriptomics data. Beyond data production, the two organizations will co-develop next-generation, AI-driven quality control metrics and predictive tools designed to optimize assay performance and automate biological insights. By integrating Bioptimus's proprietary AI models with Broad's world leading laboratory workflows, this collaboration ensures that the STELA initiative is built on a foundation of unprecedented technical precision, accelerating the development of transformative AI models for the life sciences."To unlock the true clinical potential of spatial biology, we must pair massive-scale data generation with uncompromising data quality," Niall Lennon, Chief Scientific Officer of Broad Clinical Labs added. "By combining our high-throughput laboratory workflows with Bioptimus's advanced AI, we are co-developing next-generation quality control metrics that ensure the highest data integrity. This unprecedented technical precision guarantees that the insights generated by STELA can be confidently translated into actionable clinical diagnostics and precision therapies."About BioptimusBioptimus is a global AI biotech company pioneering the world's first universal foundation model for biology. By combining cutting-edge AI with massive, multimodal, proprietary data generation, Bioptimus is building a unifying framework that connects all scales of biology, from molecules to patients, delivering interpretable, dynamic, and actionable insights. M-Optimus-1 represents the first World Model of Biology. H-Optimus, the foundation model of human histology has over 1 million downloads, and is an industry-leading model being adopted across research, drug discovery, and clinical pipelines. Bioptimus models are in use by 16 of the top 20 pharmaceutical companies.For more information about Bioptimus, visit: www.bioptimus.comMedia Contact: press@bioptimus.comAbout 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.Logo - https://mma.prnewswire.com/media/2847265/Bioptimus_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bioptimus-announces-stela-the-worlds-largest-clinically-linked-spatial-biology-atlas-alongside-key-partners-10x-genomics-and-broad-clinical-labs-302724275.html
Original: Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs
Hot Features
プレミアム
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
lambchops
1年前
novicetrader
1年前
Monksdream
2年前
T695
7年前
メールアドレスで登録
